Screener
Veradermics MANE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest income | 2,481 | 482 |
| Other income | 149 | 33 |
| Total other income, net | 2,630 | 515 |
| Loss before income taxes | (27,232) | (12,400) |
| Income tax benefit | — | — |
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's other income (expense)?
- Veradermics (MANE) reported other income (expense) of $2.63M in Q1 2026.
- How has Veradermics's other income (expense) changed year-over-year?
- Veradermics's other income (expense) increased by 410.7% year-over-year, from $515K to $2.63M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Veradermics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude